Actively Recruiting
Phase 3 Open-Label Extension Study of Plozasiran for Long-Term Treatment of Adults with Hypertriglyceridemia
Led by Arrowhead Pharmaceuticals · Updated on 2026-08-12
869
Participants Needed
255
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
This research evaluates the long-term safety and effects of plozasiran in adults with hypertriglyceridemia HTG and severe hypertriglyceridemia SHTG. Participants must have completed prior related studies and meet specific health criteria, including controlled blood sugar levels HbA1c 10%. The study is designed as an open-label Phase 3 trial to extend understanding of this treatment in these populations. Participants will receive plozasiran injections under the skin approximately every three months for two years. They will continue following a low-fat diet according to local care standards. Some participants may join based on meeting additional criteria from previous studies, ensuring they fit the trials health requirements. During the study, participants will undergo regular assessments including monitoring for treatment-related side effects and changes in blood triglyceride and cholesterol levels. Researchers will track various blood markers and cardiovascular events over 24 months. Safety and response to treatment will be closely observed throughout the trial period.
CONDITIONS
Brief Title
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
Research Team
M
Medical Monitor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
